Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Liabilities (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Total Liabilities for 6 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 15.51% to $44.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.7 million, a 15.51% increase, with the full-year FY2025 number at $44.7 million, up 15.51% from a year prior.
  • Total Liabilities was $44.7 million for Q4 2025 at Janux Therapeutics, down from $48.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $48.2 million in Q3 2025 to a low of $12.0 million in Q2 2021.
  • A 5-year average of $33.7 million and a median of $38.5 million in 2024 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 245.45% in 2022; the steepest drop was 25.38% in 2022.
  • Janux Therapeutics' Total Liabilities stood at $13.5 million in 2021, then soared by 220.59% to $43.3 million in 2022, then fell by 16.67% to $36.1 million in 2023, then grew by 7.42% to $38.7 million in 2024, then increased by 15.51% to $44.7 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Total Liabilities are $44.7 million (Q4 2025), $48.2 million (Q3 2025), and $41.7 million (Q2 2025).